To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have multiple myeloma that has returned or progressed despite at least two prior regimens of therapy which included an immunomodulating drug (such as lenalidomide or thalidomide).
- At least 3 weeks must have passed since completion of prior chemotherapy or radiation therapy and entry into the study.
- Patients must be age 18 or older.
For more information about this study and to inquire about eligibility, please contact Dr. Nikoletta Lendvai at 212-639-3368.